NCT01350999 - Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia | Biotech Hunter

Enrollment

503

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Hypertriglyceridemia

Interventions

DRUG

omega-3-acid ethyl esters 90 (TAK-085)

Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

DRUG

Eicosapentaenoic acid-ethyl (EPA)

EPA-E capsules